Pioneering for patients

In the spotlight

We are Galapagos

Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and available to patients in Europe and Great Britain for rheumatoid arthritis and ulcerative colitis, and in Japan (under a collaboration with Gilead) for rheumatoid arthritis and ulcerative colitis.

Learn more about Galapagos

News

Loading...

All Galapagos news

Events

Loading...

All Galapagos events

Job Openings

Loading...

All Current Openings